impact of phacoemulsification surgery on intraocular pressure in primary angle-closure glaucoma

impact of phacoemulsification surgery on intraocular pressure in primary angle-closure glaucoma

;Volkan Dayanır; Aykut Özdemir;Ahmet Kaplan; Esin Kırıkkaya
plasmid 2012 Vol. 42 pp. 438-442
250
dayanr2012trkimpact

Abstract

Pur po se: To investigate whether primary phacoemulsification in acute primary angle closure glaucoma (APACG) and chronic primary angle closure glaucoma (CPACG) will lower intraocular pressure (IOP) or not. Ma te ri al and Met hod: This retrospective, non-comparative, consecutive, interventional case series includes 22 eyes of 20 patients with APACG and 31 eyes of 23 patients with CPACG. All eyes had undergone phacoemulsification surgery without any reference to the presence of cataract. Data about IOP, number of antiglaucoma medications and best corrected visual acuity (BCVA) were collected. Re sults: In APACG mean IOP (95% CI), number of antiglaucoma medications and Snellen visual acuity changed at last preoperative evaluation from 30.9±15.6 mmHg (23.0-38.0), 2.6±1.4 boxes and 0.4±0.2 lines to 15.5±3.9 mm Hg (p<0.000, 13.8-17.0), 0.6±0.9 boxes (p<0.000) and 0.6±0.3 lines (p=0.001) at last follow-up. Same parameters in CPACG changed from 18.0±7.8 mmHg (15.1- 20.8), 1.6±1.1 boxes and 0.5±0.2 lines at last preoperative evaluation to 14.7±3.6 mmHg (p<0.023, 13.4-16.0), 0.5±0.8 boxes (p<0.000) and 0.6±0.3 lines (p=0.007) at last follow-up. Mean follow-up (95% CI) for APACG and CPACG were 554±646 (268-841) and 747±820 (438-1041) days respectively. In APACG and CPACG groups 19 eyes (86%) and 16 eyes (52%) had lower IOP respectively at last follow-up. 59% of the eyes with APACG and 61% of the eyes with CPACG were classified as complete success when it was defined as IOP ≤18mmHg without any antiglaucoma medications. Dis cus si on: Primary phacoemulsification without any reference to cataract is a safe and effective procedure in terms of IOP control and reducing the number of antiglaucoma drops in APACG and CPACG. (Turk J Ophthalmol 2012; 42: 438-42)

Citation

ID: 167973
Ref Key: dayanr2012trkimpact
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
167973
Unique Identifier:
10.4274/tjo.42.26056
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet